Sign in
IMVT Stock Price, Chart, Stats & News
Immunovant, Inc.
Save
6.71B
Market cap
–
Current P/E
–
Forward P/E
IMVT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.79% |
ROA | -44.11% |
ROE | -65.80% |
D/E | – |
Interest coverage ratio | – |
IMVT valuation
P/E | – |
P/S | – |
P/B | 4.41x |
P/CF | -10.29x |
P/FCF | -11.54x |
P/OCF | -10.29x |
PEG | -1.78x |
EV multiple | -12.20x |
About
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York.
Similar securities
Based on sector and market capitalization
Report issue